Table 2.

In 24 dichotomized studies (26 cohorts) comprising 1272 patients, the median survival was reported for patients in whom the IL-6 serum level was higher than the chosen cut-off value. References, primary cancer type, number of patients, cut-off for IL-6 serum level (pg/mL) and median survival are given in the table.

References	Corresponding number in Fig. 1	Tumor type	Number of patients	IL-6 cut-off (in pg/mL)	Median survival at IL-6 above chosen cut-off
Nixon et al.26	1	Advanced pancreatic cancer	84	17.5	3.8
Bachelot et al.105	2	Metastatic breast cancer	8	55	1
Bachelot et al.105	3	Metastatic breast cancer	23	13	4
Salgado et al.106	4	Metastatic breast cancer	47	6.6	9.08
Suh et al.31	5	Various advanced cancer	49	9.06	0.8
Di Nisio et al.35	6	Various advanced cancer	70	9.4	6.5
Scambia et al.118	7	Ovarian cancer	57	6	21
Chang et al.120	8	Advanced NSCLC	81	25.16	9.2
Songür et al.125	9	Advanced NSCLC	48	10	3.93
Wójcik et al.130	10	Small cell lung cancer	35	6	11
Martin et al.127	11	Lung cancer	16	130	1.6
De Vita et al.135	12	Advanced gastrointestinal ca.	34	12.53	9.4
Guida et al.139	13	Metastatic renal cell carcinoma	33	4	9
Negrier et al.140	14	Metastatic renal cell carcinoma	34	35	5
George et al.144	15	Hormone-refractory prostate cancer	95	4.8	11
George et al.144	16	Hormone-refractory prostate cancer	46	13.31	7
Hoejberg et al.150	17	Metastatic melanoma	44	4.9	4.5
Guida et al.151	18	Metastatic melanoma	25	16	7.3
Mouawad et al.152	19	Metastatic melanoma	35	19	7.9
Soubrane et al.154	20	Metastatic melanoma	76	5	9.7
Preti et al.156	21	Diffuse large-cell lymphoma	62	4.3	35
Seymour et al.157	22	Diffuse large-cell lymphoma	44	1.9	18.4
Pedersen et al.45	23	Aggressive non-Hodgkin's lymphoma	32	13	25
Kurzrock et al.162	24	Hodgkin's disease and non-Hodgkin's lymphoma	20	22	10
Yamamura et al.164	25	Adult T-cell leukemia/lymphoma	44	3.5	9.08
Trédan et al.27 (and Trédan personal communication)	26	Various cancer types: breast ca. (45%), lung ca. (15%), ovarial ca. (11%), other ca. (29%)	130	8	4